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We aimed to determine the reporting trends and characteristics of Individual Case 
Safety	 Reports	 (ICSRs)	 from	 the	 Zimbabwean	 national	 pharmacovigilance	 system.	
ICSRs	submitted	to	VigiBaseTM,	the	World	Health	Organisation's	ICSR	database	be-
tween January 1993 and December 2017 were retrospectively reviewed with re-
spect	to	the	suspected	medicine,	System	Organ	Class	(SOC),	adverse	drug	reaction	
(ADR)	type	and	seriousness,	Anatomic	Therapeutic	Chemical	(ATC)	group,	age,	and	
gender.	In	total,	4071	ICSRs	were	submitted	to	VigiBaseTM from targeted spontane-
ous reporting (n =	2909;	71.5%),	vaccine	surveillance	(n	=	679;	16.7%),	and	passive	
spontaneous reporting (n =	483;	11.9%),	 respectively.	The	median	age,	 ICSR	com-
pleteness	score	and	timeliness	of	reporting	were	34.0	years	(IQR:	14.0;	43.0),	0.90	
(IQR:	0.70;	1.00),	 and	548.0	days	 (IQR:	266:1131),	 respectively.	More	 than	half	of	
the ICRS were from female patients (n =	2233;	54.9%).	Antiretrovirals,	antibiotics,	
vaccines,	and	anti-tubercular	medicines	were	reported	in	62.9%,	27.9%,	16.7%,	and	
13.3%	of	submitted	ICSRs,	respectively.	The	most	frequent	ADRs	involved	the	skin	
and subcutaneous systems (n =	1111;	20.5%),	nervous	system	(n	=	733;	13.5%),	and	







reporting system which potentially captures a variety of therapeutic classes.
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1  | INTRODUC TION
The safety information on any medicinal product initially derives 
from	 pre-clinical	 studies	 and	 randomized	 controlled	 trials	 during	
drug	 development.	 However,	 this	 information	may	 not	 include	 all	
possible	adverse	drug	reactions	(ADRs)	because	of	factors	such	as	
controlled	clinical	trial	conditions	and	small	sample	sizes.1	Therefore,	
post-marketing	 surveillance	 (PMS)	 provides	 important,	 additional	
safety information from millions of patients.2,3	 In	 light	of	 this,	 the	
World	 Health	 Organisation	 (WHO)	 formed	 the	 Programme	 for	
International	 Drug	Monitoring	 (PIDM)	 in	 1968	 to	 collect	 as	many	
ADRs	from	diverse	populations	to	best	reflect	and	capture	the	ag-
gregate safety profiles of individual medicines.4,5	 This	 global	ADR	





known	 despite	 training	 and	 analytical	 support	 from	 the	 UMC.6,7 
Developed countries contribute the majority of individual case 
safety	 reports	 (ICSRs)	 in	 VigiBaseTM,4	 whilst	 Africa	 contributes	
a	mere	0.88%	of	 the	 cumulative	 global	ADR	data.8 Most of these 
ADRs	are	related	to	antibiotics	in	contrast	to	the	rest	of	the	world	
where cardiovascular and neurological medicine related ICSRs pre-
dominate.3,8 These observations reflect the unevenly distributed 
global	 disease	 burden,	 different	 drug	 utilization	 patterns,	 cultural	
norms,	 and	 medical	 practices.2	 Furthermore,	 limited	 resources,	
government	support	and	the	over-reliance	on	donor	funded	public	
health programmes may explain the preponderance for antibiotic 
related	 ICSRs	 in	Africa.9	Moreover	50%	of	SSA	countries	 lack	 the	
legal	mandate	to	monitor	ADRs	and/or	engage	market	authorization	
holders in PMS activities.8,9	Consequently,	the	ADR	profile	of	some	
medicines	 is	 inadequately	 reflected	 in	 their	 summary	 of	 product	
characteristics.
Zimbabwe	 previously	 boasted	 one	 of	 Africa's	 most	 robust	
healthcare	systems,	but	over	the	past	few	years	it	has	been	stag-
nating due to decreasing government healthcare expenditure.10,11 
HIV/AIDS	and	tuberculosis	have	also	contributed	to	the	strain	on	
resources necessitating donor funding for service provision.10,11 
However,	 pharmacovigilance	 activities	 for	 HIV	 and	 tuberculosis	
medicines have disproportionately been supported from donor 
funded public health programmes for the respective diseases.12 
Non-communicable	 diseases	 such	 as	 diabetes	 mellitus	 and	 hy-
pertension have been steadily increasing13 and are projected to 
increase	markedly	in	people	living	with	HIV.14 Due to limited phar-
macovigilance	funding,	the	majority	of	any	collated	ADRs	are	ex-




rently	 utilizes	 passive	 spontaneous	ADR	 reporting,	 vaccine	 safety	
surveillance and targeted spontaneous reporting (TSR) to collect 
unsolicited	 ADRs,	 adverse	 events	 following	 immunization	 (AEFIs)	
and	anti-retroviral	and/or	anti-tubercular	medicine	related	ADRs	re-
spectively. Stimulated reporting through TSR started in 201215 after 
its	promulgation	by	 the	WHO	as	 a	 simple,	 inexpensive	PV	 tool	 to	







Given	the	importance	of	continuous	ADR	data	analysis,18 we set 
out	 to	evaluate	 the	 trends	and	characteristics	of	Zimbabwean	de-




2  | MATERIAL S AND METHODS
2.1 | Study design
A	 retrospective	 descriptive	 analysis	 of	 anonymized	 ICSR	 data	
from	Zimbabwe	collected	during	 the	period	1	January	1993	 to	31	
December 2017 was conducted. The ICSR data was extracted from 
VigiBaseTM	using	VigiLyze®,	the	database's	search	and	analysis	soft-
ware	tool	on	2018-10-06	(dataset	date:	2018-09-30).	We	included	
ICSRs meeting the minimum criteria for regulatory reporting in ac-
cordance	 with	 the	 International	 Conference	 on	 Harmonisation	 of	




ing	 to	 the	Medical	Dictionary	 for	Regulatory	Activities	 (MedDRA)	
version	21.0	System	Organ	Class	(SOC),	whereas	the	ICHE2A	guide-
line's	definitions	were	used	to	define	serious	ADRs.20,21	All	PTs	were	
mapped to the corresponding primary SOC using the Bioportal 
MedDRA	ontology	 repository.22 Only the main SOC affected was 
coded for each ICSR. The information about the pharmacological 
subgroup	 was	 classified	 according	 to	 the	 Anatomical	 Therapeutic	
K E Y W O R D S
adverse	drug	reaction,	drug	safety,	pharmacovigilance,	post-market	surveillance,	spontaneous	
reporting system
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Chemical	 (ATC)	 Classification	 system	 at	 level	 2	 for	 the	 suspected	
medicines.23	In	this	system,	drugs	are	divided	into	five	different	lev-
els	based	on	the	system	or	organ	on	which	they	act;	their	chemical,	




ported into a Microsoft Office ExcelTM package for further analysis 
(Microsoft	 Corporation,	 Redmond,	WA,	 USA).	 The	 timeliness	 of	 re-
porting	was	calculated	by	subtracting	the	date	of	onset	of	ADR	from	
the	date	of	VigiBaseTM entry.26 Where the date for the onset of the 
ADR	was	incomplete,	the	first	day	of	the	month	was	used,	otherwise	




Descriptive statistical methods were used to analyse the surveil-
lance	data.	We	used	the	ANOVA	to	compare	continuous	variables	
and	the	chi-square	test	or	Fischer's	exact	 tests	were	used	for	cat-
egorical	 variables,	 as	 appropriate.	 Poisson	 regression	 analysis	was	
done	using	the	number	of	ADRs	as	the	dependent	variable	and	age,	
gender,	ATC	drug	therapeutic	class,	number	of	drugs,	and	reporter	
type as independent variables. The Statistical Package for Social 
Sciences	 (SPSS)	version	22.0	 (IBM	Corporation,	Somers,	NY,	USA)	
and	Stata	12	(StataCorp	LLC,	College	Station,	TX,	USA)	were	used	
for the statistical analyses and for graphing the analyses respec-
tively.	All	statistical	tests	were	done	at	the	5%	significance	level.
2.4 | Ethical considerations
Ethical exemption for the study was granted by the Medical Research 
Council	 of	 Zimbabwe	 (MRCZ	 Ref:	 MRCZ/E/207).	 The	 exemption	
was granted because ICSR data collection is a routine surveillance 
programme	which	uses	anonymized	data.
3  | RESULTS
3.1 | Characteristics of the pharmacovigilance 
system
A	 total	 of	 4126	 ICSRs	were	 extracted	 from	VigiBaseTM for the pe-
riod	 under	 review.	 Of	 these,	 4071	 ICSRs	met	 the	 inclusion	 criteria	
and	the	average	number	of	ADRs	per	ICSR	was	1.33	± 0.70 and the 
median	 number	 of	 ADRs28	 per	 ICSR	 was	 1.0	 (range:	 1-7).	 The	me-
dian	time	between	the	date	of	ADR	occurrence	and	the	date	of	ICSR	
entry	in	VigiBaseTM	was	548.0	days	(IQR:	266.0-1131.0).	The	median	
VigiGradeTM	 completeness	 score	was	 0.90	 (IQR:	 0.70-1.00),	 indicat-
ing	well-documented	ICSRs	according	to	Bergvall	et	al27 The majority 
of the ICSRs were collected through the TSR programme (n = 2909; 
71.5%) and the vaccine safety surveillance programme (n = 679; 16.7%) 
as	shown	in	Figure	1.	Passive	spontaneous	ADR	reporting	contributed	
483	 (11.9%)	 ICSRs.	 Nurses	 (n	=	 2767;	 68.0%)	 reported	 the	 highest	
number	of	ICSRs,	followed	by	medical	doctors	(n	=	989;	24.3%),	phar-
macists (n =	195;	4.8%),	and	consumers	(n	= 5; 0.1%).
3.2 | Characteristics of the ICSRs
3.2.1 | Demographic characteristics
The	 demographic,	 reporter	 and	 reporting	 characteristics	 are	 shown	
in	Table	1.	A	 total	 of	 2233	 (54.9%)	 of	 the	 ICSRs	were	 recorded	 for	
females	and	1792	 (44.0%)	were	 for	males	 indicating	an	overall	0.80	









The annual number of ICSRs gradually increased during the study 
period.	No	 reports	were	 captured	 into	VigiFlow®	 in	 the	 calendar	
years	1994,	1997,	and	2002.	However,	a	marked	increase	in	the	num-
ber of reports was noted starting in 2003. The increase in reporting 
of	ICSRs	was	particularly	notable	for	anti-retroviral	medicines	(J05)	
and	vaccines	(J07)	as	shown	in	Figure	2.
3.3 | Characteristics of the adverse drug reactions
The	frequency	of	at	 least	one	serious	ADR	was	30.6%	of	the	total	
ICSRs.	Among	serious	ADRs,	life	threatening	ADRs	(n	=	522;	12.8%)	
F I G U R E  1   Schematic showing the overall distribution of all 
ICSRs	extracted	from	VigiBase®
All extracted ICSRs (4126)
AEFI surveillance (679) Targeted Spontaneous 
Reporting (2909)
Regular Spontaneous ADR 
Reporting (483)
Excluded (55): ADR not 
specified (16); suspect drug 
not specified (30); both 
ADR and suspect drug not 
specified (9)








935 ICSRs (23.0%) had no specified outcome (missing information). 
Children	under	one	year	had	the	highest	death	rate	(14.2%;	56/395)	
followed	by	the	20-65	year	age	group	(3.5%;	83/2370).
The	 most	 frequent	 ADRs	 by	 SOC	 involved	 the	 skin	 and	 sub-
cutaneous systems (n =	 1111;	 20.5%),	 nervous	 system	 (n	= 733; 
13.5%),	and	gastrointestinal	disorders	(n	=	654;	12.1%)	as	shown	in	
Table 2. The skin and subcutaneous tissue disorders also had the 
highest number of reported PTs per SOC followed by the nervous 
and gastrointestinal systems respectively. The 10 most commonly 






compared	 to	 patients	 who	 received	 antiretrovirals	 (5.2%),	 antihy-
pertensive	 agents	 (8.0%),	 and	 antibacterial	 agents	 (8.2%).	 Poisson	
regression	analysis	indicated	that	the	number	of	ADRs	a	patient	ex-
perienced	was	associated	with	the	therapeutic	class	 (ATC	code)	of	
the prescribed medicine (P = .001) as shown in Table 3. Patient age 
(P =	.858),	gender	(P =	.362),	reporter	qualification	(P =	.093),	and	the	
number of drugs a patient was on (P = .539) were not related to the 
number	of	ADRs	the	patient	experienced.
3.4 | Characteristics of the drugs






TA B L E  1  Demographic,	reporter,	and	reporting	characteristics
Characteristic Total (N = 4071) Vaccine (n = 679) TSR (n = 2909)
Passive spontaneous 
reporting (n = 483) P-value
Age/years	(mean	± SD) 30.90 ±	18.43 4.61	±	5.83 37.16 ± 13.97 30.15 ± 20.99 <.001
Gender	(M:F	ratio) 0.80 1.10 0.76 0.73 <.001
ADR/ICSR	ratio 1.33 1.52 1.26 1.52 –
Timeliness/days 
(mean ± SD)
857.47	±	855.56 1180.86	±	740.37 810.91	±	859.84 683.27	±	870.94 <.001
Completeness (mean ± SD) 0.81	± 0.20 0.78	± 0.15 0.84	± 0.20 0.71 ± 0.22 <.001
Reporter type
Nurse 2767	(68.0%) 609 1911 247 <.001
Pharmacist 195	(4.8%) 9 132 54
Physician 989	(24.3%) 42 817 130
Consumer 5 (0.1%) 0 1 4
Not	specified 115	(2.8%) 19 48 48
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Our analysis shows that the total number of collected ICSRs has 
been	 steadily	 increasing	 in	 line	 with	 African	 and	 international	
trends.4,8,29,30	The	sharp	 increase	 in	 the	number	of	 ICSRs	 in	2004	
may be explained by the increase in the number of public health 
programmes	supported	by	development	partners.	However,	marked	
increases in ICSRs mainly followed the introduction of active surveil-
lance	programmes	in	Zimbabwe.	The	cohort	event	monitoring	(CEM)	
of	artemisinin-based	combination	therapies	(ACTs)	surveillance	pro-






virals	 and	 antitubercular	 drugs	 in	 2012.	 The	 TSR	 active	 ADR	 sur-
veillance programme partially explains the sharper increases in ICSR 
submissions	 in	 2012.	 However,	 from	 in-house	 experience,	 ICSR	
entry	 into	VigiFlow	depended	on	adequate	staffing	potentially	ex-
plaining the observed ICSR trends. ICSRs were mainly submitted by 
healthcare workers in contrast to European trends where lawyers 
and the pharmaceutical industry contribute a significant proportion 
to the total number of submitted ICSRs.29 The latter has mostly been 
driven	by	strict	legal	reporting	requirements	which	are	not	present	
in	most	African	nations.25,29 The markedly high reporting by nurses 
possibly shows a success of the TSR programme because its main 
purpose	was	to	task	shift	ICSR	reporting	to	non-physician	cadres.16 
In	 addition,	 the	nurse	driven	 ICSR	 submission	 reflects	 the	 greater	
dependency of healthcare delivery in district hospitals on nurses as 
observed for the TSR programme and in Togo.15,31
The	most	frequently	reported	SOCs	were	skin	and	subcutaneous	
tissue	 disorders,	 gastrointestinal	 disorders,	 general	 disorders	 and	
administration	 site	 conditions,	 and	 the	 nervous	 system	 disorders.	
TA B L E  2  Distribution	of	ADRs	by	system	organ	class
System organ class
Most commonly reported preferred term
SOC contribution to 
total PT count/ (n/%)Preferred term (PT)
PT contribution to SOC count/ 
(n/%)
Blood and lymphatic system disorders Anaemia 119	(47.0) 253	(4.7)
Cardiac disorders Cardiomyopathy 12 (13.6) 88	(1.6)
Congenital,	familial	and	genetic	disorders Talipes 6	(85.7) 7 (0.1)
Eye disorders Eye inflammation 8	(14.6) 55 (1.0)
Gastrointestinal disorders Vomiting 246	(37.6) 654	(12.1)
General disorders and administration site 
conditions
Pyrexia 135	(31.8) 424	(7.8)
Hepatobiliary	disorders Hepatitis 22 (31.9) 69 (1.3)
Immune system disorders Stevens-Johnson	Syndrome 109	(38.3) 285	(5.3)
Infections and infestations Pneumonia 20	(31.8) 63 (1.2)
Injury,	poisoning	and	procedural	complications Injection site abscess 130 (51.0) 255	(4.7)
Metabolism and nutrition disorders Hepatic	enzyme	increased 26 (10.0) 260	(4.8)
Musculoskeletal and connective tissue disorders Pain in extremity 64	(1.2)
Neoplasms	benign,	malignant	and	unspecified	(incl	
cysts and polyps)
Pathological fracture 6 (35.3) 17 (0.3)
Nervous	system	disorders Neuropathy	peripheral 298	(40.7) 733 (13.5)
Pregnancy,	puerperium	and	perinatal	conditions Pregnancy 37 (53.6) 69 (1.3)
Psychiatric disorders Psychotic disorder 17 (19.1) 89	(1.6)
Renal and urinary disorders Renal impairment 42	(35.9) 117 (2.2)
Reproductive system and breast disorders Gynaecomastia 418	(82.6) 506 (9.3)
Respiratory,	thoracic	and	mediastinal	disorders Cough 30 (56.6) 53 (1.0)
Skin and subcutaneous tissue disorders Rash 705 (63.5) 1111 (20.5)
Vascular	disorders Deep vein thrombosis 18	(26.5) 68	(1.3)
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This	is	similar	to	the	Nigerian,	Togolese,	Colombian,	French,	Turkish	
and overall global findings.4,25,31-34	However,	some	differences	are	
notable	between	the	Zimbabwean	and	French	PV	schemes	on	the	
prominence	of	blood,	lymphatic	system,	and	immune	system	disor-
ders in the latter. The observed differences may be due to the var-
ied	ADR	reporting	practices	 in	addition	to	differences	 in	 the	most	
administered	ATC	groups	within	 these	 countries.4 Moreover most 
ICSRs	were	 reported	 for	medicines	 in	 the	ATC	group	J	with	a	sig-
nificantly	higher	proportion	of	anti-retrovirals	as	previously	shown	
in	 other	 low	 income	 countries	 such	 as	 Togo	 and	Nigeria.4,8,31,34,35 
In	 contrast,	 cardiovascular	 and	 nervous	 system	medications	were	
more	 frequently	 reported	 in	 developed	 countries,	 such	 as	 France	
and Germany.29,32	The	ADRs	in	Colombia	and	Portugal	were	mostly	
attributed	 to	 anti-infectives	 for	 systemic	use	 followed	by	nervous	
and cardiovascular system medicines.33,36
The	quality	of	 ICSR	reporting	as	 indicated	by	 ICSR	timeliness	
and completeness is comparable to the global average but lags be-
hind some established European pharmacovigilance schemes. The 
median	time	between	the	date	of	onset	of	an	ADR	and	the	date	of	
reporting	to	VigiBaseTM of 2.35 years is comparable to the global 
average	 of	 2.40	 years.4,26	 However,	 the	 median	 timeliness	 was	
much	longer	than	the	73	days	observed	in	France	and	the	330	days	
observed	 in	Uganda.32,37 Timeliness has been noted to differ de-
pending	on	the	reporter	qualification,	the	administered	ATC	groups	
and	the	number	of	reported	ADRs	per	ICSR.32,37	Furthermore,	the	
median	 ICSR	 completeness	 score	 of	 0.80	 is	 significantly	 higher	
than	 the	 0.41	 for	 VigiBaseTM	 as	 a	whole,	 but	 comparable	 to	 the	
yearly	 averages	 observed	 in	 the	 Indian	 PV	 scheme.27,38 Regular 
refresher	ADR	 reporting	 trainings	 for	 healthcare	practitioners	 in	
Zimbabwe	may	 explain	 the	 observed	 differences.38 Deficiencies 
TA B L E  3  Poisson	regression	analysis	results	for	the	number	of	reported	ADRs/ICSR
Parameter
Hypothesis test 95% Wald CI for RR
Number of outcomes Wald chi-square P value Relative risk (RR) Lower limit Upper limit
Reporter	qualification 3786 6.407 .093
Reporter	qualification	= physician 960 .039 .844 1.078 .510 2.280
Reporter	qualification	= nurse 2648 .014 .907 1.046 .495 2.212
Reporter	qualification	= pharmacist 173 .290 .590 1.230 .578 2.617
Reporter	qualification	= consumer 5 . . 1 . .
Patient gender 3786 .833 .362
Patient gender = female 2105 .833 .362 1.027 .970 1.087
Patient gender = male 1681 . . 1 . .
Number	of	recorded	drugs 3786 8.930 .539
Number	of	recorded	drugs	= 1 464 1.944 .163 .445 .143 1.389
Number	of	recorded	drugs	= 2 404 1.717 .190 .467 .149 1.459
Number	of	recorded	drugs	= 3 1385 1.911 .167 .448 .144 1.398
Number	of	recorded	drugs	=	4 978 1.994 .158 .441 .141 1.374
Number	of	recorded	drugs	= 5 300 1.902 .168 .449 .144 1.401
Number	of	recorded	drugs	= 6 113 1.554 .213 .483 .154 1.517
Number	of	recorded	drugs	= 7 63 2.159 .142 .420 .132 1.335
Number	of	recorded	drugs	=	8 61 1.662 .197 .468 .148 1.484
Number	of	recorded	drugs	= 9 15 1.410 .235 .480 .143 1.612
Number	of	recorded	drugs	= 10 2 .008 .929 1.065 .265 4.285
Number	of	recorded	drugs	= 12 1 . . 1 . .
ATC	code 3786 23.044 .001
ATC	code	= C02 23 .500 .479 .876 .606 1.265
ATC	code	= J01 124 3.669 .055 .812 .657 1.005
ATC	code	=	J04AM 403 2.591 .107 .866 .727 1.032
ATC	code	=	J05AR 2372 10.419 .001 .771 .658 .903
ATC	code	= J07 637 .448 .503 .941 .787 1.125
ATC	code	= P02 113 .149 .699 .956 .763 1.199
ATC	code	= others 114 . . 1 . .
Patient age 3786 .032 .858 1.000 .998 1.002
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in the timeliness of ICSRs indicate some immaturity of the 
Zimbabwean	PV	scheme	and	an	area	in	need	of	improvement	com-
pared	to	 long	established	PV	schemes	of	 ICH	member	countries.	
This	 could	potentially	be	 remedied	by	strengthening	 the	PV	sys-
tem	through	introduction	of	PV	specific	legislation	enforcing	ICSR	
reporting	and	decentralizing	the	national	PV	system	like	in	France	
and Germany.29,32	 Decentralization	 could	 also	 increase	 the	 effi-
ciency	and	transparency	of	the	national	PV	scheme.39
The	ATC	code	had	an	influence	on	the	number	of	reported	ADRs	
whilst	patient	 age,	 gender	 and	 the	number	of	prescribed	medicines	





nificant disability/incapacitation were more common in males as pre-
viously observed in Italy and Sweden.41,44 In contrast to the general 
trend,	the	male	to	female	ratio	was	higher	in	children	under	5	years	





higher	HIV	prevalence	was	noted	 in	 this	age	group.34,35 The overall 
predominance of female ICSRs could be due to underlying physiologi-
cal	differences,	females’	higher	medical-care	seeking	behavior	and	use	
of more prescriptions compared to males.46,47
Despite	the	notable	growth	in	the	Zimbabwean	pharmacovigi-
lance	scheme,	mandatory	reporting	by	market	authorization	holders	
should be considered in order to increase ICSR reporting. In addi-
tion,	 decentralization	 of	 ICSR	 collection	 to	 provincial	 and	 district	
healthcare	 facilities	 and	 the	 utilization	 of	mobile	 phone	 ADR	 re-
porting platforms can strengthen the collation and completeness of 
ADR	data.	The	latter	measures	may	reduce	barriers	to	reporting	and	
extend	the	reach	and	availability	of	ADR	reporting	platforms	to	all	
relevant stakeholders including patients as observed in Kenya.48,49 
Furthermore,	 it	 is	 critical	 to	provide	 relevant	 feedback	 to	health-
care practitioners to provide meaning and an appreciation of ICSR 
reporting.30	This	could	subsequently	help	stimulate	ICSR	reporting,	
thereby increasing the numbers and spectrum of the submitted 
ICSRs. It is important to regularly review the performance of the 
scheme as a basis for informing regulatory measures.29 The spec-
trum of ICSRs could also be increased by encouraging the submis-
sion	of	ADRs	from	other	therapeutic	areas	beyond	anti-infectives.
The	inherent	limitations	of	a	study	based	on	spontaneous	ADR	
reports	 include	under-reporting	 and	 the	 inability	 to	 calculate	 inci-
dence rates because of the unavailability of exposure/denomina-
tor data.32,42	While	 ICSR	 data	 is	 voluntarily	 submitted,	 stimulated	
reporting through TSR introduced bias especially regarding the 
observed	 ADR,	 ATC,	 and	 SOC	 profiles.	 The	 ICSRs	 were	 skewed	
towards	 anti-retroviral	 drugs,	 anti-tubercular	 medicines	 and	 vac-
cines as would be expected given the dominance of public health 
programmes	targeting	HIV,	tuberculosis,	and	immunization.	The	ob-
served	profiles	may	also	indicate	the	prescription	patterns,	prevalent	
diseases	 and	 acute,	 severe	 and/or	well-known	ADRs.50 The major 
strength of the current study is in highlighting areas in need of im-




macovigilance scheme is based on a limited therapeutic spectrum 
of	medicines	and	may	underestimate	the	ADR	burden.	 In	addition,	
there is need to improve the timeliness of ICSRs to enable further 
case reviews and timely signal detection.
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